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Summary The GER human pancreatic carcinoma cell line possesses receptors for 1,25-dihydroxyvitamin D3. We report that the vitamin D
analogue EB 1089 inhibits the growth of these cells in vitro and when grown as tumour xenografts in immunodeficient mice. Tumour-bearing
mice were given EB 1089 at a dose of 5gg kg-' bodyweight i.p. thriceweeklyfor4-6 weeks. Tumourgrowth wassignificantly inhibited in treated
animals compared with controls in the absence of hypercalcaemia. These findings may havetherapeutic implications in pancreatic cancer.
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Carcinoma of the exocrine pancreas is an increasingly common
cancer but no effective chemotherapy has been developed for
patients with advanced disease. Initially, the presence ofoestrogen
receptors (ER) in this tumour suggested that it might be responsive
to endocrine therapy (Andren-Sandberg and Backman, 1990;
Poston et al, 1990), but clinical trials with the anti-oestrogen
tamoxifen have not proved to be encouraging (Bakkevold et al,
1990; Taylor et al, 1993; Wong and Chan, 1993).
Receptors for another steroid hormone, 1,25-dihydroxyvitamin
D3 [1,25(OH)2D3, the active form ofvitamin D3] are also present in
GER, anextensively characterized cell line derived from aprimary
human pancreatic adenocarcinoma thathas been shown toproduce
xenografts in nude mice (Grant et al, 1979, 1992, 1993). 1,25-
(OH)2D3 is known to inhibit the proliferation in vitro of a number
of established cancer cell lines (Colston et al, 1981; Frampton et
al, 1983; Dokoh et al, 1984), but its potent calcium-mobilizing
activity in vivo limits its potential as a therapeutic agent in hyper-
proliferative disorders. Recently, new synthetic analogues of
vitamin D have been developed that have been shown to exhibit
potent anti-tumour effects in animal models of breast cancer
without causing marked hypercalcaemia (Abe et al, 1991; Colston
et al, 1992a and b). These analogues are currently under evalua-
tion in phase MI/I trials in patients with breast cancer. In this
preliminary report, we have extended our study of these
compounds to pancreatic carcinoma and have assessed the effects
ofthe synthetic vitamin D analogue EB 1089 on both the progres-
sion of xenografts developed from GER pancreatic adenocarci-
noma cells and the growth ofcultured pancreatic adenocarcinoma
cells in vitro. Our results demonstrate that this novel vitamin D
analogue exhibits significant anti-tumour activity both in vitro and
in vivo, suggesting it should be considered as a potential candidate
for therapy in pancreatic carcinoma.
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MATERIALS AND METHODS
Compounds
Vitamin D derivatives [1,25(OH)2D3 and EB 1089] were gifts from
Leo Pharmaceutical Products, Denmark, and 9-cis retinoic acid was
supplied by Hoffmann-La Roche (Nutley, NJ, USA). lax,25-dihy-
droxy [26,27-methyl-3H]cholecalciferol (180 Ci mmol-') and
2,4,6,7-[3H]oestradiol (100 Ci mmol-1) were obtained from
Amersham International (Amersham, Bucks, UK). Tissue culture
medium and reagents were purchased from Gibco (Paisley,
Strathclyde, UK). All other analytical grade reagents were obtained
from Sigma (Poole, UK), unless otherwise stated.
Cellular effects
GER pancreatic carcinoma cells (Grant et al, 1979) were seeded
into 24-well plates (2 x 104 cells per well) and were cultured in
RPMI 1640 medium supplemented with 2.5% fetal calf serum,
2 mm glutamine, 100 U penicillin ml-' and 100 jg streptomycin
ml-' at 37°C in a humidified atmosphere of5% carbon dioxide for
24 h before treatment. EB 1089 or 9-cis retinoic acid was added in
ethanol (0.1% final media concentration) to give final concentra-
tions of0.1-100 nm. Controls received ethanol alone and medium
was changed every second day. Cell number was assessed by
crystal violet assay (Wosikowski et al, 1993). MCF-7 breast and
MIA PaCa-2 pancreatic cancer cells were routinely maintained in
Dulbecco's modified Eagle medium (DMEM) supplemented with
5% fetal calf serum.
Western analysis and ligand binding
ER and vitamin D receptor (VDR) and p53 expression in cell
cultures were determined by Western analysis. MCF-7 breast and
GER pancreatic carcinoma cells were treated over a period of 1-4
days with EB 1089 (10nM). After treatment, cell lysates were
prepared as previously described (James et al, 1994). Equivalent
protein extracts (5-15 gg) were electrophoresed on 10% SDS poly-
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Figure 1 Expression of VDR, ER and P53 in GER pancreatic and MCF-7
carcinoma cells (A) Scatchard analysis of [3H]1,25(OH)2D3 and [3H]173
oestradiol specific binding in GER pancreatic carcinoma cell cystosol. Aliquots
of cell cytosol were incubated with increasing concentrations of
[3H]1,25(OH)2D3 or [3H] 17j oestradiol at 4°C for 16 h. Non-specific binding
was determined at each concentration by inclusion of 100-fold molar excess
of radio-inert hormone. Bound and free hormones were separated by dextran
coated charcoal (ER) or by the hydroxylapatite method (VDR).(B) Western
analysis of ER in whole-cell lysates of GER pancreatic and MCF-7 breast
cancer cells. Replicate samples (15 pg of total protein) from GER and MCF-7
cells were run on 10% SDS-polyacrylamide mini-gels and blotted as described
in Materials and methods. Lane 1 untreated, Lane 2 untreated but with fresh
medium added to cultures 24 h before preparation of cell lysates. (C) Effects
of EB 1089 on expression of VDR protein and p53 expression in GER
pancreatic and MCF-7 breast carcinoma cells. Cell cultures were treated over
a 96-h period with ethanol vehicle or 1OnM EB 1089. Lysates were prepared
for Western analysis and immunoprobed with VDR or p53 antibodies. For
VDR expression in both cells lines, lane 1 shows control cultures and lane 2
shows EB 1089 treated cultures. For p53 expression in GER cells: lane 1,
control (24 h); lane 2, EB 1089 (24 h); lane 3, control (48 h); lane 4, EB 1089
(48 h); lane 5, control (96 h); lane 6, EB 1089 (96 h). For p53 expression in
MCF-7 cells: lane 1, control (96 h); lane 2, EB 1089 (96 h)
Figure 2 Effects of EB 1089 on growth of GER pancreatic carcinoma cells
in vitro (A) GER pancreatic carcinoma cells were seeded into 24-well plates
(2 x 104cells per well) and cultured in RPMI-1640 medium for 24 h before
treatment with increasing concentrations of EB 1089 (1-100 nM) for 9 days.
Cell number, assessed by crystal violet assay, is expressed as % control
cultures treated with ethanol vehicle alone. ***P < 0.005. (B) Anti-proliferative
effects of EB 1089 and 9-cis retinoic acid on GER pancreatic cancer cells.
GER pancreatic carcinoma cells were seeded into 24-well plates (2 x 104
cells per well) and cultured in RPMI-1640 medium for 24 h before treatment
with 1OOnM EB 1089 or 1OOnM 9-cis retinoic acid. Control cultures received
ethanol vehicle alone. On selected days, cell number was assessed by
crystal violet assay as described in Materials and methods. Results are
means ± sem with six replicate determinations at each time point. *P < 0.05;
***P < 0.005 compared with cell cultures treated with ethanol vehicle
acrylamide gels. Total protein was quantitated by the Bradford
method (Bradford, 1976), with uniform loading being confirmedby
Coomassie blue staining ofreplicate gels. Electrophoresed proteins
were transferred onto Hybond C-Super nitrocellulose membrane
(Amersham, Bucks, UK) and immunoprobed with a rat monoclonal
antibody recognizing mammalian VDR (Chemicon International,
Harrow, UK), the ER monoclonal rat antibody H222 (Abbott
Laboratories, Chicago, IL, USA) or the mouse monoclonal anti-
body to p53, which recognizes wild-type and mutant forms (Ab-6,
Oncogene Science, NY, USA). Antibody binding was revealed
with a peroxidase-labelled sheep anti-mouse IgG secondary anti-
body (ER and VDR) or peroxidase-labelled sheep anti-mouse IgG
secondary antibody (p53). Specific proteins were visualized by
enhanced chemiluminescence (ECL, Amersham, UK). A linear
relationship was observed between the amount of total lysate
protein electrophoresed and the signal intensity. Receptor levels
were quantitated by ligand binding assay (McGuire and De La
Garza, 1973; Colston et al, 1986; James et al, 1994).
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Figure 3 Effects of EB 1089 on growth of GER pancreatic carcinoma cells in
vivo (A) Effect of EB 1089 (5 pg kg body weight i.p. three times a week) on
the progression of GER pancreatic xenografts over 28 days of treatment.
Results, expressed as the percentage change in tumour volume from day 0,
are shown as means ± sem (n = 7). Statistical comparisons were made using
the non-parametric Mann-Whitney U-test. **P<0.01; *** P< 0.005. (B)
Comparison of EB 1089 (5 pg kg-' i.p. thrice weekly) and 5-fluorouracil
(20 mg kg-' i.p. thrice weekly) on progression of GER pancreatic carcinoma
xenografts over 6 weeks of treatment. Results are expressed as the
percentage change in tumour volume from day 0 (mean ± sem. n = 9).
Treatment with EB 1089 significantly inhibited tumour progression
compared with controls (*P < 0.05 **P< 0.01 Mann-Whitney U-test). At
6 weeks of treatment, serum calcium concentration in animals treated with
this dose of EB 1089 was not significantly different from controls (mean
2.35 ± 0.11 mmol-' 2.27 ± 0.08 mmol-' in controls). Difference in percentage
change in tumour volume between 5-fluorouracil treated and control groups
was not significant at any time point
Animal protocol
Female nude (Nu/Nu, MFI strain) mice, 6-8 weeks of age (Olac,
UK) were maintained on sterilized tap water and irradiated
standard rodent chow. GER pancreatic tumour xenografts were
developed as previously described (Grant et al, 1979), and mice
bearing palpable tumours (0.2-0.4 cm in diameter) were randomly
assigned to treated orcontrol (vehicle-alone) groups. EB 1089 was
given intraperitoneally in 0.1 ml of propylene glycol/0.05 M
disodium hydrogen phosphate (4:1, v/v). Tumour volume was
determined weekly as previously described (Colston et al, 1992a).
No tumour exceeded 1.2 cm in diameter or 10% of total body
weight. Atthe end ofeach experiment animals were exsanguinated
under halothane anaesthesia and serum was stored at -20°C until
analysed.
Statistical methods
Percentage change in total tumour volume at each week of study
was compared between groups using the non-parametric
Mann-Whitney U-test. Comparisons of the biochemical and in
vitro studies used the unpaired Student's t-test.
RESULTS
Ligand binding assays with cytosols from GER pancreatic carci-
noma cells showed that the cells were VDR positive (63 fmol mg-'
cytosol protein) but these cells did not contain detectable amounts
of ER (Figure IA). A similar pattern of receptor expression was
seen with MIA PaCa-2 cells (VDR 24 and ER <1 fmol mg-'
cytosol protein). ER protein could not be detected by Western
analysis in GER cells but was readily detected in MCF-7 breast
cancer cells (Figure 1B). VDR protein was detected by Western
blot analysis in both GER and MCF-7 cell lines and treatment of
these cells with 10 nM EB 1089 for 4 days increased the level of
VDR protein (Figure IC). In MCF-7 cells, EB 1089 increased p53
protein levels at 4 days. Treatment ofGER cells with EB 1089 for
24, 48 and 96 h revealed no appreciable difference in p53 protein
levels relative to controls (Figure IC).
Cell proliferation studies showed that the analogue EB 1089
produced a dose-dependent inhibition ofthe growth ofGER cells.
Maximal effects were seen at a concentration of 100 nm (Figure
2A). Inhibition of growth was also observed over a period of 8
days with the vitamin D analogue and also with the same concen-
tration (100 nM) of9-cis retinoic acid (Figure 2B).
The effects of EB1089 on in vivo pancreatic carcinoma growth
were evaluated using GER tumour xenografts. Dose regimens
were chosen on the basis of our previous findings in rats, which
have indicated that the elimination half-life of EB 1089 is in the
order of 3-5 h (Binderup et al, 1991). Initially, the analogue was
given intraperitoneally to mice bearing tumour xenografts at doses
of 2.5 and 5 gg kg-' body weight three times a week for 4 weeks.
At a dose of 5 ,ug kg-' thrice weekly, EB 1089 caused significant
inhibition ofgrowth (Figure 3A). Mean serum calcium in controls
was 2.19 ± 0.053 mmol 1-' and 2.49 ± 0.074 mmol 1-' in the treated
group (P < 0.01). There was no significant difference in body
weight between control and treated groups at 4 weeks and
treated animals remained healthy. However, animals treated with
5 jig kg-' five times weekly showed weight loss after 2 weeks of
treatment (mean serum calcium in animals treated with this dose
regimen was 2.81 ± 0.068 mmol 1-'). At this time, mean tumour
volume was 85% ofinitial value. With the lower dose (2.5 jig kg-'
thrice weekly), differences between treated and control groups
were not significant at 28 days (P = 0.24). Finally, effects of EB
1089 (5 jg kg-' thrice weekly) were compared with those of 5-
fluorouracil (20 mg kg-'). Figure 3B illustrates the tumour growth
curves with these two agents. At the end of the 6 week treatment
period, significant inhibition of tumour progression was observed
in the group receiving EB 1089 (P = 0.007). However, differences
between 5-fluorouracil-treated and control groups were not signif-
icant (P = 0.068 Mann-Whitney U-test).
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DISCUSSION
Our studies demonstrate that pancreatic adenocarcinoma cells
possess specific receptors for 1,25(OH)2D3 (VDR) and are func-
tionally responsive to the growth inhibitory effects of the vitamin
D analogue EB 1089 both in vitro and in vivo. As far as we are
aware, this is the first demonstration that a vitamin D derivative
may demonstrate in vivo anti-tumour effects in a xenograft model
ofpancreatic adenocarcinoma. At a dose of 5 ,tg kg-' body weight
thrice weekly, EB 1089 inhibited progression of established
tumours in the absence of hypercalcaemia; animals did not lose
weight and remained healthy. At the present time, the mechanisms
by which EB 1089 may exert inhibitory effects on the growth of
these pancreatic carcinoma cells is not clear. In MCF-7 breast
cancer cells, the vitamin D analogue binds to VDR and strongly
inhibits the proliferation of these cells with a potency 50-100
times that of 1,25(OH)2D3 (Colston et al, 1992b; Mathiasen et al,
1993). It has also been demonstrated that EB 1089 increases
expression of p53 protein in MCF-7 cells (James et al, 1995),
which acts as a cell cycle checkpoint regulator (Kuerbitz et al,
1992). However, our preliminary findings presented here indicate
that the effects ofEB 1089 on GER cell growth are independent of
changes in p53 expression.
Inhibitory effects of retinoids on the growth of human pancre-
atic cancer cells in vitro and in vivo have recently been reported
(Bold et al, 1996) and EB 1089 has been demonstrated to enhance
the growth-inhibitory effects of all-trans retinoic acid in certain
pancreatic carcinoma cell lines (Zugmaier et al, 1996). Our studies
have additionally demonstrated that EB 1089 and 9-cis retinoic
acid act separately to inhibit the growth of GER cells. We have
already demonstrated that these compounds act in a co-operative
manner to enhance induction ofapoptosis in MCF-7 breast cancer
cells (James et al, 1995); these observations, together with our
present findings with pancreatic carcinoma cells, may have thera-
peutic implications. It is also important to note that neither of the
two pancreatic carcinoma cell lines studied possessed oestrogen
receptors. The absence of these receptors in some tumours may
well account for the limited success of tamoxifen therapy in
pancreatic carcinoma.
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